<?xml version="1.0" encoding="UTF-8"?>
<p>Human monoclonal antibodies specific for the SARS-CoV-2 virus might represent a possible passive serotherapy for selected patients. Several SARS-CoV monoclonal antibodies with in vitro neutralizing activity were generated from B lymphocytes of patients that recovered from the 2003 epidemic. A single human monoclonal antibody with cross-neutralizing activity against SARS-CoV and SARS-CoV-2 was recently reported [
 <xref rid="B157-vaccines-08-00224" ref-type="bibr">157</xref>], however no clinical experience or recruiting trials are available at the moment.
</p>
